Advertisement
UK markets open in 42 minutes

  • NIKKEI 225

    37,076.00
    -1,003.70 (-2.64%)
     

  • HANG SENG

    16,129.04
    -256.83 (-1.57%)
     

  • CRUDE OIL

    84.41
    +1.68 (+2.03%)
     

  • GOLD FUTURES

    2,398.50
    +0.50 (+0.02%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    49,887.62
    +577.46 (+1.17%)
     

  • CMC Crypto 200

    1,283.30
    -29.32 (-2.23%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

Orion is planning to renew its R&D strategy and organisation

Orion Oyj
·2-min read

ORION CORPORATION PRESS RELEASE 10 SEPTEMBER 2020 at 2.00 p.m. EEST

Orion is planning to renew its R&D strategy and organisation

Orion is planning to change and refocus the strategy of its R&D function. The planned changes and renewal of the organisation are intended to strengthen the company's R&D portfolio and speed up the progress of research projects. The changes will affect the entire R&D organisation, and the company will launch co-operation negotiations on this in Finland.

The reorganisation of R&D requires changes to the function's focus areas, organisational structure and reporting relationships, and there are production grounds for the changes.

ADVERTISEMENT

In order to implement the planned changes and refocusing of Orion's R&D and the organisational changes that support these, Orion will launch co-operation negotiations concerning its R&D function (over 500 employees) in Finland – in Espoo, Turku and Kuopio. The negotiations will concern all members of staff in all personnel groups in R&D in Finland.

The company has today issued a negotiation proposal, as laid down in the Finnish Act on Co-operation within Undertakings, on the reorganisation of operations and possible personnel reductions. The operational changes and reorganisations are anticipated to result in changes to responsibilities, transfers to new roles, transfers to different locations, changes to the terms of employment and possible layoffs on production grounds.

The negotiations may result in personnel reductions of a maximum of 25 persons. The plan is to implement some of the possible personnel reductions through retirement, part-time work and training opportunities. The company may also transfer persons affected by the negotiations to other roles in the group. Should redundancies occur, they would take place during 2020.


Further information:

Outi Vaarala
Senior Vice President, R&D, Orion Corporation
Tel. +358 50 966 3472
outi.vaarala@orionpharma.com


Jouni Turunen
Vice President, HR, Orion Corporation
Tel. +358 50 426 2821
jouni.turunen@orion.fi

Contact person for the media:

Terhi Ormio
Vice President, Communications, Orion Corporation
Tel. +358 50 966 4646
terhi.ormio@orion.fi

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi/en

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.